Background
Former senior House health policy advisor. Architect of major FDA and public health legislation. Trusted counsel on drug innovation, access and emergency preparedness.
With more than a decade of senior service in the U.S. House of Representatives, Stephen Holland brings expertise in health care policy strategy. He advises clients on matters related to the Food and Drug Administration (FDA), health care innovation, public health infrastructure, prescription drug pricing, health care coverage and reimbursement. Stephen leverages his experience to help clients navigate the legislative process, shape health policy and respond to congressional oversight.
Stephen served as senior counsel on the House Energy and Commerce Committee under current Ranking Member and former Chairman Frank Pallone (D-NJ), where he led legislative efforts involving the FDA, the Biomedical Advanced Research and Development Authority (BARDA) and the 340B drug pricing program. He was the lead negotiator on the Food and Drug Omnibus Reform Act of 2022 (FDORA), a sweeping package of more than 50 policies to accelerate medical innovation and strengthen regulatory oversight.
During the COVID-19 pandemic, Stephen played a central role in securing billions of dollars for vaccine development, testing and treatment through the Coronavirus Aid, Relief and Economic Security (CARES) Act, the FY2021 Omnibus bill and the American Rescue Plan Act. Earlier in his career, as counsel to Representative Kurt Schrader (D-OR), he led the creation of the Competitive Generic Therapy pathway at FDA, which expanded access to affordable medicines by promoting generic drug competition.
Credentials
EDUCATION
J.D., 2013, Washington and Lee University School of Law
B.A., 2010, St. John’s University
ADMISSIONS
Virginia
District of Columbia
